Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain (RAQUEL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03692403 |
|
Recruitment Status :
Completed
First Posted : October 2, 2018
Last Update Posted : October 4, 2022
|
Sponsor:
Ferring Pharmaceuticals
Information provided by (Responsible Party):
Ferring Pharmaceuticals
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Endometriosis-related Pain | Drug: Quinagolide 360 µg Drug: Quinagolide 720 µg Drug: Quinagolide 1080 µg Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 22 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing Efficacy, Safety, Dose-response of Quinagolide Vaginal Rings Administered Sequentially for 4 Menstrual Cycles in Women With Moderate-Severe Endometriosis-related Pain |
| Actual Study Start Date : | November 28, 2018 |
| Actual Primary Completion Date : | February 14, 2022 |
| Actual Study Completion Date : | February 14, 2022 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Endometriosis
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Quinagolide 360 µg
Vaginal ring containing Quinagolide 360 μg, with daily target release rate of 4.5 μg
|
Drug: Quinagolide 360 µg
Vaginal ring containing quinagolide 360 µg for daily releases
Other Name: FE 999051 |
|
Experimental: Quinagolide 720 µg
Vaginal ring containing Quinagolide 720 μg, with daily target release rate of 9 μg
|
Drug: Quinagolide 720 µg
Vaginal ring containing quinagolide 720 µg for daily releases
Other Name: FE 999051 |
|
Experimental: Quinagolide 1080 µg
Vaginal ring containing Quinagolide 1080 μg, with daily target release rate of 13.5 μg
|
Drug: Quinagolide 1080 µg
Vaginal ring containing quinagolide 1080 µg for daily releases
Other Name: FE 999051 |
|
Placebo Comparator: Placebo
Vaginal ring containing matching placebo
|
Drug: Placebo
Matching placebo |
Primary Outcome Measures :
- Changes in the mean daily Numerical Rating Scale (NRS) scores compared to baseline for the worst endometriosis related pain. [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
Secondary Outcome Measures :
- Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst endometriosis-related pain on days with menstrual bleeding and for the worst endometriosis-related pain on days with no menstrual bleeding [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
- Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst endometriosis-related pain. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
- Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst dysmenorrhea. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
- Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst non-menstrual pelvic pain. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
- Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst dyspareunia on days with sexual intercourse. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
- Frequency of avoiding sexual intercourse due to expected pain [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed daily by participants in an e-Diary
- Changes in the mean daily scores for the worst impact of endometriosis-related pain on the subject's ability to function. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed daily by participants in an e-Diary.
- Changes in the mean weekly scores of the Endometriosis Health Profile-30 (EHP-30) pain impact domain. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed weekly by participants in an e-Diary. EHP-30 is a quality-of-life questionnaire. Score ranges from 0-100 and lower score denotes improvement.
- Changes in vaginal bleeding pattern. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed participants by subjects in an e-Diary
- Percentage of days with mild and/or strong rescue analgesics used [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed daily by participants in an e-Diary
- Total and average doses of mild and/or strong rescue analgesics used [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed daily by participants in an e-Diary
- Responder rate [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed as ≥30%, ≥50% and ≥70% reduction from the baseline in mean daily NRS score for the worst endometriosis-related pain, dysmenorrhea and non-menstrual pelvic pain and for the worst endometriosis-related pain impact
- Changes in the mean individual and total symptom and sign severity scores [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed by the Biberoglu and Behrman (B&B) scale which is a 4-point scale with 0=none and 3=severe.
- Changes in the Endometriosis Health Profile-30 (EHP-30) scores [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed by the EHP-30 quality-of-life questionnaire completed by subjects. Score ranges from 0-100 with lower score denoting improvement.
- Changes in Patient Global Impression of Severity (PGIS) scores [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed by the PGIS scale completed by participants. PGIS is a 6-point scale depicting a subject's rating of their current conditions from "good" to "bad".
- Patient Global Impression of Change (PGIC) scores [ Time Frame: At cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed by the PGIC scale completed by participants. PGIC is a 7-point scale depicting a patient's rating of their overall improvement from "good" to "bad".
- Plasma concentration of quinagolide and metabolites [ Time Frame: Within 5 days after first ring insertion and at around 1 month, 3 months, 3.5 months and 4 months after baseline (each cycle is approximately 28 days) ]Assessed by blood samples collection
- Serum levels of mid-luteal phase progesterone [ Time Frame: At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days) ]Assessed by blood samples collection
- Proportion of subjects with serum mid-luteal progesterone levels ≥25 nmol/L (7.9 ng/ml) [ Time Frame: At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days) ]Assessed by blood samples collection
- Serum levels of mid-luteal estradiol, prolactin, thyroid-stimulating hormone (TSH) and insulin-like growth factor-1 (IGF-1) [ Time Frame: At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days) ]Assessed by blood samples collection
- Changes in bone turnover markers, determined by bone resorption marker serum C-terminal crosslinking telopeptide of type 1 collagen (s-CTx) and bone formation marker serum procollagen type I N propeptide (s-PINP) [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed by blood samples collection
- Number of subjects with no changes, non-significant changes and significant changes in ECG [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed by 12-lead ECG
- Proportion of subjects with abnormal clinically significant echocardiography findings indicating valvular heart disease [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed by echocardiography
- Proportion of subjects identified with potential impulse control disorders [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed by the questionnaire for impulsive-compulsive disorders completed by subjects
- Frequency and intensity of adverse events [ Time Frame: From signing informed consent through study completion, around 7 months ]Assessed by an Adverse Events Log completed by the Investigator
- Changes in circulating levels of clinical chemistry parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months) and cycle 5 (around 5 months, each cycle is approximately 28 days) ]Assessed by blood samples collection
- Changes in circulating levels of clinical haematology parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months) and cycle 5 (around 5 months, each cycle is approximately 28 days) ]Assessed by blood samples collection
- Changes in urinalysis parameters (protein, glucose, bilirubin, pH, nitrite, ketone, urobilinogen, blood, leukocytes, and specific gravity) [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed by urine sample collection (dip-stick test)
- Proportion of participants with markedly abnormal changes in circulating levels of clinical chemistry parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months) and cycle 5 (around 5 months, each cycle is approximately 28 days) ]Assessed by blood samples collection
- Proportion of participants with markedly abnormal changes in circulating levels of clinical haematology parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months) and cycle 5 (around 5 months, each cycle is approximately 28 days) ]Assessed by blood samples collection
- Proportion of participants with markedly abnormal changes in urinalysis parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed by urine samples collection
- Frequency and intensity of ring acceptability parameters [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]Assessed by a questionnaire completed by participants, addressing ring insertion/removal, any feeling of the ring while the ring is in the body, any feeling of the ring during sexual intercourse if applicable and any experience of ring falling out or breaking.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Pre-menopausal females aged ≥18 years at time of signing informed consent(s).
- Body mass index (BMI) of 18-42 kg/m2 (both inclusive) at screening.
- Initial confirmation of endometriosis by laparoscopy or laparotomy within the last 10 years before the run-in visit or visualization of persistent endometrioma by repeat ultrasound.
- Transvaginal ultrasound documenting a uterus with no clinically significant abnormalities and presence of at least one ovary with no clinically significant abnormalities (with the exception of endometrioma) at the run-in visit.
- Having moderate to severe endometriosis-related pain.
- Willing to use a non-hormonal barrier method (i.e. condom) for contraception from randomization to the end-of-trial. This is not required if adequate contraception is achieved by vasectomy of the sexual partner or surgical sterilisation of the subject.
- Willing to avoid the use of vaginal douches or any other intravaginally administered medications or devices from randomization to the end of treatment.
- Willing to change usual analgesics to rescue analgesics as permitted by protocol for endometriosis-related pain from the start of run-in to the end-of-trial.
Exclusion Criteria:
- Use of depot medroxyprogesterone acetate (MPA) within 10 months of the start of run-in.
- Use of gonadotropin releasing hormone (GnRH) agonists (3 months depot) or dopamine agonists within 6 months of the start of run-in.
- Use of GnRH agonists (1 month depot) or intrauterine device within 3 months of the start of run-in.
- Use of GnRH antagonist, combined oral contraceptive pill or progestin-only pill within 1 month of the start of run-in.
- Undiagnosed abnormal vaginal bleeding.
- History of no relief of endometriosis related pain after any medical therapy or surgery. However, history of partial pain relief, discontinuation due to side effects are not exclusionary.
- Known bone diseases (e.g. osteoporosis, Paget's disease and osteomalacia) affecting bone resorption or bone formation markers.
- Any significant abnormal findings of heart examinations before randomization.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03692403
Locations
Show 43 study locations
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
| Study Director: | Global Clinical Compliance | Ferring Pharmaceuticals |
| Responsible Party: | Ferring Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT03692403 |
| Other Study ID Numbers: |
000165 |
| First Posted: | October 2, 2018 Key Record Dates |
| Last Update Posted: | October 4, 2022 |
| Last Verified: | October 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Endometriosis Quinagolide Dopamine Agonists Dopamine Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |